Quarterly ResultAug 5, 2026, 04:22 PM
Zevra Q2 Net Revenue Up 53% to $39.7M; Cash Position $260.2M
AI Summary
Zevra Therapeutics reported strong financial results for the second quarter ended June 30, 2026, with net revenue increasing 53% year-over-year to $39.7 million, primarily driven by MIPLYFFA sales. The company maintained a robust cash position of $260.2 million and highlighted significant progress in its commercial execution for MIPLYFFA and pipeline development for celiprolol. Zevra also announced a request for re-examination of its Marketing Authorisation Application for arimoclomol in Europe.
Key Highlights
- Q2 2026 net revenue was $39.7 million, a 53% increase over Q2 2025.
- MIPLYFFA net revenue contributed $30.2 million to Q2 2026 total revenue.
- Cash, cash equivalents, and investments stood at $260.2 million as of June 30, 2026.
- Net income for Q2 2026 was $8.8 million, or $0.14 per basic and diluted share.
- Adjusted net income for Q2 2026 was $15.2 million, or $0.25 per diluted share.
- 14 MIPLYFFA prescription enrollment forms received in Q2 2026, totaling 184 since launch.
- 66 patients enrolled in the Phase 3 DiSCOVER trial for celiprolol, with 4 enrolled in Q2 2026.
Price Impact
More from ZVRA